Advance in application of rituximab in refractory minimal change disease
10.3760/cma.j.cn431274-20221222-01335
- VernacularTitle:利妥昔单抗在难治性微小病变性肾病中的应用进展
- Author:
Yao CHEN
1
;
Yixiong HUANG
;
Ying CHEN
;
Yumei LIANG
Author Information
1. 湖南省人民医院（湖南师范大学附属第一医院）肾内科，长沙 410002
- Keywords:
Rituximab;
Minimal change disease;
Nephrotic syndrome
- From:
Journal of Chinese Physician
2023;25(5):794-797
- CountryChina
- Language:Chinese
-
Abstract:
Minimally degenerative nephropathy is one of the common types of primary nephrotic syndrome, and it is currently believed that B lymphocytes are closely related to its pathogenesis. Patients with refractory small degenerative kidney disease require treatment with glucocorticoids combined with immunosuppressant. Rituximab is a monoclonal antibody that consumes B cells. Its use in the treatment of patients with refractory microdegenerative kidney disease can reduce recurrence rate, prolong remission period, and reduce hormone exposure. However, there is no consensus on the treatment plan and adverse reaction response measures, and multicenter, prospective, and large-scale research answers are still needed. This article summarizes the latest progress of rituximab in the treatment of refractory minimal degenerative kidney disease, hoping to provide assistance for the development of clinical treatment strategies.
